Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for breast cancer, retiring the standalone policy and replacing it with Section 220.6.17, effective May 15, 2026. Here's what billing teams need to do.
This is a structural policy consolidation, not a quiet administrative cleanup. The Centers for Medicare & Medicaid Services is folding its FDG PET breast cancer coverage guidance into Section 220.6.17 of the National Coverage Determinations Manual, retiring the previous standalone policy. The policy does not list specific CPT or HCPCS codes in the available data—but PET imaging for breast cancer billing is high-dollar, high-scrutiny territory, and any coverage policy shift deserves your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | FDG PET for Breast Cancer — Retired, Replaced with Section 220.6.17 |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Radiology, Nuclear Medicine, Hematology/Oncology |
| Key Action | Audit all FDG PET breast cancer claims against Section 220.6.17 criteria before May 15, 2026 |
CMS FDG PET Breast Cancer Coverage Criteria and Medical Necessity Requirements 2026
The old standalone NCD for FDG PET in breast cancer is gone. CMS is now governing this through Section 220.6.17, which consolidates PET imaging coverage under a unified framework.
This matters because the coverage policy your team has been citing—and your MAC has been adjudicating against—is being retired. Any internal billing guidelines, payer correspondence templates, or denial appeal language that references the old standalone policy needs to be updated before May 15, 2026.
CMS FDG PET coverage policy for breast cancer has historically been one of the more nuanced areas in oncology billing. Coverage has turned on specific clinical scenarios: initial treatment strategy, subsequent treatment strategy, restaging, and suspected recurrence. Medical necessity documentation requirements differ by indication, and Medicare Administrative Contractor interpretation has varied by region.
The consolidation into Section 220.6.17 does not automatically mean the criteria are identical to what they were under the prior policy. That's the critical assumption your billing team cannot make. Pull Section 220.6.17 directly from the NCD Manual and compare it line by line against what your practice has been using. If you're not sure how the new criteria map to your patient population, loop in your compliance officer before the effective date of May 15, 2026.
Medical necessity documentation for FDG PET scans under Medicare has always required specificity—treating physician attestation, the clinical question being answered, and the stage or treatment status of the patient. That requirement does not soften with a policy consolidation. If anything, a restructured NCD is a signal that CMS is tightening its framework, not loosening it.
Prior authorization is not universally required for PET imaging under Medicare fee-for-service, but Medicare Advantage plans vary. If your breast cancer patients are MA enrollees, check each plan's prior authorization requirements separately. A coverage policy change at the NCD level does not automatically cascade into MA plan policy updates on the same timeline.
CMS FDG PET for Breast Cancer Exclusions and Non-Covered Indications
The available policy data does not provide a detailed list of exclusions specific to Section 220.6.17. However, based on CMS's historical coverage framework for FDG PET in oncology, there are patterns your billing team should anticipate.
CMS has traditionally limited FDG PET reimbursement for breast cancer to specific oncologic decision points. Screening use—absent a clinical question about staging or treatment—has not been covered. Routine surveillance without evidence of recurrence has been a recurring source of claim denial.
The retirement of the standalone policy creates a window of ambiguity. Until your MAC publishes updated guidance that explicitly references Section 220.6.17, you may see inconsistent adjudication. Document everything. If a claim is denied citing the retired policy, that's grounds for an appeal with a clear audit trail.
Coverage Indications at a Glance
The policy data provided does not include a detailed, indication-level breakdown for Section 220.6.17. The table below reflects CMS's established PET coverage framework for breast cancer, which Section 220.6.17 now governs. Verify each row against the actual NCD Manual text before using this as a billing reference.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Initial treatment strategy (staging) | Covered (when medical necessity criteria met) | Not specified in available policy data | Documentation of treating physician's clinical question required |
| Subsequent treatment strategy | Covered (when medical necessity criteria met) | Not specified in available policy data | Must support a change in treatment decision |
| Restaging after treatment completion | Covered (when medical necessity criteria met) | Not specified in available policy data | Clinical basis for restaging must be documented |
| Suspected recurrence | Covered (when medical necessity criteria met) | Not specified in available policy data | Symptom or lab finding triggering the study must be documented |
| Routine surveillance without clinical indication | Not Covered | Not specified in available policy data | Consistent with CMS's oncology PET framework |
| Screening (no prior diagnosis) | Not Covered | Not specified in available policy data | PET not covered for breast cancer screening under Medicare |
CMS FDG PET for Breast Cancer Billing Guidelines and Action Items 2026
The retirement of a standalone NCD and its replacement with a consolidated section is an event that requires active billing team response. This is not a "file and forget" change.
| # | Action Item |
|---|---|
| 1 | Pull Section 220.6.17 from the NCD Manual now. Don't wait until May 14, 2026. The NCD Manual is publicly available at cms.gov. Read the full text of 220.6.17. Compare it side by side with the retired policy your team has been referencing. |
| 2 | Update your internal billing guidelines before May 15, 2026. Any internal documentation, charge capture guides, or coding reference sheets that cite the old standalone FDG PET breast cancer NCD need to be revised. Update the policy citation to Section 220.6.17. |
| 3 | Audit your MAC's local coverage determination landscape. Your Medicare Administrative Contractor may publish an LCD that complements or clarifies Section 220.6.17 for your region. Check your MAC's website and sign up for their policy update alerts. MAC-level interpretation will drive actual claim adjudication. |
| 4 | Review your denial patterns on FDG PET breast cancer claims. If you've had claim denial patterns on PET imaging for breast cancer over the past 12 months, pull those claims now. Understanding why they were denied under the old policy tells you where your medical necessity documentation is weak—and that weakness doesn't disappear under 220.6.17. |
| 5 | Confirm prior authorization requirements for every Medicare Advantage plan in your payer mix. The NCD governs traditional Medicare. Your MA contracts may have different prior authorization requirements for FDG PET, and a CMS NCD update does not automatically trigger a corresponding MA plan update. Call your MA payer contacts or check each plan's portal before May 15, 2026. |
| 6 | Update your appeal templates. Any denial appeal letter that cites the retired standalone policy needs a new version citing Section 220.6.17. Appeals submitted after May 15, 2026, that reference a retired policy will look sloppy to MACs and may slow resolution. |
| 7 | Brief your nuclear medicine and radiology coding staff. The people entering charges need to know the policy citation changed. A five-minute team communication before May 15, 2026, prevents downstream billing errors. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for FDG PET Breast Cancer Under Section 220.6.17
The policy data provided does not list specific CPT, HCPCS, or ICD-10 codes for this policy change. Do not assume codes from the retired standalone policy carry over unchanged to Section 220.6.17 without verifying against the actual NCD Manual text.
For FDG PET imaging billing, your team should pull the applicable codes directly from Section 220.6.17 and cross-reference with your MAC's LCD. The relevant code types to look for include PET scan procedure codes and oncology diagnosis codes for breast cancer—but confirm every code against the published policy before updating your charge capture.
If your billing consultant or coding team needs a verified code list for FDG PET breast cancer claims under 220.6.17, that audit should happen before May 15, 2026, not after your first denied claim.
What This Change Actually Means for Oncology Billing Teams
Here's the honest read on this change: consolidation policies like this are often administratively driven, not clinically driven. CMS periodically reorganizes its NCD Manual to reduce redundancy and bring related policies under unified sections.
That's bureaucratically sensible. For billing teams, it creates a specific kind of risk. Your team has institutional memory around the old policy number and its criteria. That memory may not perfectly match what Section 220.6.17 says. The mismatch between assumed criteria and actual criteria is exactly where claim denial risk lives.
FDG PET scans are not low-dollar claims. A single denied PET study represents meaningful reimbursement exposure. Multiply that across a busy oncology practice's monthly volume, and this is a change worth taking seriously—not just flagging and moving on.
The other risk is timing. The effective date of May 15, 2026, falls mid-month. Claims submitted for dates of service on or after May 15 need to align with 220.6.17. Claims for dates of service before May 15 still adjudicate under the prior framework. Train your billing team to apply the right criteria based on date of service, not the date the claim is submitted.
If you're uncertain about how your specific patient mix and documentation practices align with the new section, talk to your compliance officer before May 15, 2026. This is exactly the kind of structural policy change where a quick internal audit now prevents a costly appeals backlog later.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.